Searched for
SUVEN LIFESCIENCES
Cohance Lifesciences announces $10 million investment in US-based armCohance Lifesciences is investing USD 10 million to expand bioconjugation capabilities at its US subsidiary, NJ Bio, enhancing its ADC solu...- Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and ...
- National Company Law Tribunal clears Casper Pharma’s merger with Suven PharmaceuticalsThe NCLT Mumbai has approved the merger of Casper Pharma with Suven Pharmaceuticals. This merger aims to improve efficiency, reduce costs, ...
- Suven Pharmaceuticals names Vivek Sharma as executive chairmanSuven Pharma, backed by Advent International, has appointed Vivek Sharma as the new executive chairman effective September 20. Sharma bring...
- Pharma raw material makers in race to tank up on CXO talentSome of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded ...
- Merger effect! Suven Pharma shares jump 15% in 2 daysAfter the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...
- Suven, with Cohance and more, wants to become a CDMO powerhouse: Annaswamy Vaidheesh, executive chairman"We want to be a diversified, end-to-end capability outsourcing partner, serving customers from development to commercial scale. Doing this...
- Suven Pharmaceuticals shares soar 13% on proposed merger with Cohance LifesciencesShares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry po...
- Stocks in news: Suven Pharma, MOIL, Adani stocks, ICICI Lombard, VedantaSuven Pharmaceuticals and Cohance Lifesciences signed a definitive agreement to merge their businesses, which will further strengthen the f...
- Suven-Cohance Lifesciences merger announced to create 1st listed PE-led contract manufacturer in Indian pharmaSuven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...
- Suven Pharma, Cohance Lifesciences to merge to bolster CDMO businessPromoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significan...
- ADIA, HarbourVest eye minor stake in CohanceADIA and HarbourVest are in discussions to acquire a minority stake in Cohance Lifesciences, a pharmaceuticals platform owned by Advent Int...
- PE Advent completes acquisition of Suven Pharma, appoints new Board and management teamPrivate equity firm Advent International has completed its majority acquisition of Indian contract development and manufacturing organisati...
- Suven Pharma falls 2% as Advent picks majority stake in the companyPost the completion of this acquisition, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences with Suven, to...
- Advent closes in on Suven Pharma buyoutPromoters Venkateswarlu Jasti and his family split Suven Life Sciences in FY20, turning the CRAMS business into a separately listed company...
- Sameer Gehlaut buys Indiabulls Housing shares and other top bulk deals of the daySameer Gehlaut, Chairman of Indiabulls Group bought 23 lakh shares of Indiabulls Housing on Thursday at Rs 96.56 per share.
- Suven Lifesciences Q2 net down 7.17 pc to Rs 2.33 crSuven Lifesciences' net profit declined by 7.17% to Rs 2.33 crore for the second quarter ended September 30, 2010, over the same period pre...
- Suven Lifesciences can move back to 55-60 levels: Devangvisaria.comDevang Visaria, chief strategist, Devangvisaria.com, in a chat with ET Now talks about Suven Lifesciences.
- Switch from Piramal Lifesciences to some other pharma stocks for long term: Deepak MohoniDeepak Mohoni, Director, trendwatchindia.com in a chat with ET Now talks about Piramal Lifesciences and Suven Lifesciences.
- Suven Life lines up $45-m expansionSuven Lifesciences, is planning to scale up its drug discovery development and support services.
Load More
